| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1002/14651858.CD006995.PUB2 |
| P698 | PubMed publication ID | 26725721 |
| P50 | author | Sarah Bendall | Q61807601 |
| P2093 | author name string | Sarah E Hetrick | |
| Lisa J Phillips | |||
| Belinda Garner | |||
| P2860 | cites work | A rating scale for depression | Q24564540 |
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Rapid reversal of psychotic depression using mifepristone | Q28191073 | ||
| Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder pa | Q28238749 | ||
| DST studies in psychotic depression: a meta-analysis | Q28253516 | ||
| A rating scale for drug-induced akathisia | Q28258433 | ||
| Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial | Q28286363 | ||
| Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study | Q29615116 | ||
| Meta-analyses involving cross-over trials: methodological issues | Q29620304 | ||
| Imputing missing standard deviations in meta-analyses can provide accurate results | Q29620610 | ||
| Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. | Q30573727 | ||
| The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis | Q33693510 | ||
| Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease | Q33885755 | ||
| Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia | Q33885798 | ||
| Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics | Q33987036 | ||
| Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms | Q34153146 | ||
| Treatment of Acute Mental Disorders with an Adrenal Steroid | Q34220836 | ||
| 6 beta-Hydroxy-3:5-cyclopregnan-20-one in mental states. | Q34242432 | ||
| Clinical and biological effects of mifepristone treatment for psychotic depression | Q34450697 | ||
| Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder | Q34547629 | ||
| Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression | Q34554362 | ||
| Lifetime prevalence of psychotic and bipolar I disorders in a general population | Q34596831 | ||
| A depression rating scale for schizophrenics | Q68663014 | ||
| Treatment of schizophrenia with a vasopressin analogue | Q68863678 | ||
| The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome | Q70601646 | ||
| Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II | Q71374902 | ||
| Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo | Q71572180 | ||
| Intensive cortisone therapy in schizophrenia | Q73969844 | ||
| Desoxycortone acetate and ascorbic acid in the treatment of schizophrenia | Q75703639 | ||
| Responses of treatment-refractory chronic schizophrenics to chlorpromazine with concurrent adrenocortical steroid | Q78795164 | ||
| Lifetime prevalence of psychotic disorders in Finland is 3.1% | Q80673117 | ||
| Issues in the meta-analysis of cluster randomized trials | Q34906716 | ||
| The unit of analysis error in studies about physicians' patient care behavior | Q35553582 | ||
| Mood and Cognitive Changes During Systemic Corticosteroid Therapy | Q35665808 | ||
| Statistics notes. Trials randomised in clusters | Q36246100 | ||
| Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology | Q36407072 | ||
| Effectiveness of early intervention in psychosis | Q36728402 | ||
| Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? | Q36778605 | ||
| The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. | Q36787614 | ||
| Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal | Q37188995 | ||
| Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials | Q37479869 | ||
| Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis | Q40404354 | ||
| Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. | Q40454295 | ||
| Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials | Q40824415 | ||
| Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. | Q43295955 | ||
| Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo | Q43854988 | ||
| Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: a pilot study | Q44246724 | ||
| Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia | Q44309868 | ||
| A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition | Q44717873 | ||
| Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder | Q44917858 | ||
| Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia | Q44953308 | ||
| An open label trial of C-1073 (mifepristone) for psychotic major depression | Q46152690 | ||
| Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study | Q46484497 | ||
| What does the PANSS mean? | Q46570213 | ||
| Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial | Q46673333 | ||
| Clinical implications of Brief Psychiatric Rating Scale scores | Q46732006 | ||
| Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia | Q46768213 | ||
| Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients | Q46844697 | ||
| The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects | Q46908282 | ||
| Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia | Q48186144 | ||
| The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research | Q48186899 | ||
| Is mifepristone useful in psychotic depression? | Q48368636 | ||
| Glucocorticoid interactions with memory function in schizophrenia | Q48454260 | ||
| Stress and HPA-axis functioning in young people at ultra high risk for psychosis | Q48475359 | ||
| Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. | Q51908211 | ||
| Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. | Q51912536 | ||
| Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. | Q51953902 | ||
| Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. | Q52067896 | ||
| Corticosteroids in psychiatric patients: subacute and diurnal effects on free fatty acid and catecholamine metabolism. | Q52118312 | ||
| Ineffectiveness of vasopressin in the treatment of memory impairment in chronic schizophrenia. | Q52213120 | ||
| The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. | Q52882919 | ||
| Pituitary volume in psychosis | Q57403366 | ||
| Stress, the Hippocampus and the Hypothalamic-Pituitary-Adrenal Axis: Implications for the Development of Psychotic Disorders | Q60636744 | ||
| Placebo response in psychotic depression. | Q64969215 | ||
| The effect of diagnosis and age on the DST: a metaanalytic approach | Q67926431 | ||
| P433 | issue | 1 | |
| P921 | main subject | psychosis | Q170082 |
| glucocorticoid | Q422549 | ||
| P304 | page(s) | CD006995 | |
| P577 | publication date | 2016-01-04 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Antiglucocorticoid and related treatments for psychosis |
Search more.